Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nabilone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nabilone SCHEMBL33339 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL17223864 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL11268571 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL2762240 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL563809 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL13759779 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615666 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL29448222 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| Nabilone SCHEMBL15520922 | 1.00 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL11615083 | 0.99 | CNR2 (0.98) | CNR2CNR1NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083161-A1 | CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS | NATURAL EXTRACTION SYS LLC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4496886-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | Ginkgo Bioworks, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-4486332-A1 | CANNABINOID DOSAGE FORM | Emyria (AU) | 2025-01-08 | — | — | EP | disclosed |
| US-20230340446-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | GINKGO BIOWORKS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023183857-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | GINKGO BIOWORKS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4179077-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | Ginkgo Bioworks, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| EP-4168553-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | Ginkgo Bioworks, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4149447-A1 | USES AND FORMULATIONS OF CANNABINOIDS | ADD Advanced Drug Delivery Technologies, Ltd. (CH) | 2023-03-22 | — | — | EP | disclosed |
| EP-4149446-A1 | USES AND FORMULATIONS OF CANNABINOIDS | ADD Advanced Drug Delivery Technologies, Ltd. (CH) | 2023-03-22 | — | — | EP | disclosed |
| EP-4127149-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | Ginkgo Bioworks, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-110545807-B | Cannabinoid formulations for the treatment of dermatitis and inflammatory skin disorders | 博塔尼克斯制药有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220323401-A1 | FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF ACNE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2022-10-13 | — | — | US | disclosed |
| US-20220313621-A1 | FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF PSORIASIS | Botanix Pharmaceuticals Ltd. | 2022-10-06 | — | — | US | disclosed |
| EP-4065093-A1 | NEISSERIA TREATMENT USING CANNABINOIDS | Botanix Pharmaceuticals Ltd (AU) | 2022-10-05 | — | — | EP | disclosed |
| CN-115066234-A | Antibacterial treatment using cannabinoids and active agents | 博塔尼克斯药物有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-115003290-A | Treatment of neisseria using cannabinoids | 博塔尼克斯药物有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114945353-A | Controlled release formulations of highly lipophilic physiologically active substances | 埃德先进药物输送技术有限责任公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-114929197-A | Controlled release formulations of highly lipophilic physiologically active substances | 埃德先进药物输送技术有限责任公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-3986395-A1 | ANTIBACTERIAL DOSAGE REGIME USING CANNABINOIDS | Botanix Pharmaceuticals Ltd (AU) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022066700-A1 | INFRARED SPECTROSCOPIC METHODS FOR EVALUATING COMPOSITIONS | CENTRAL COAST AGRICULTURE, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083161-A1 | CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS | CNR2, CNR1, OPRD1 | CNR1 2/4885CNR2 1/4885NR1I2 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.